Chronic progressive multiple sclerosis

This phase 3 trial tests whether rituximab, a cheaper drug, works as well as ocrelizumab for active multiple sclerosis. About 600 adults with relapsing or progressive MS will receive one of the two drugs. The main goal is to see if rituximab can prevent new brain lesions as effec…

This study tests the long-term safety of the drug tolebrutinib in 2,500 adults with relapsing or progressive multiple sclerosis. Participants previously took part in earlier trials and will continue taking tolebrutinib or a placebo for up to several years. The goal is to see if t…

This early-stage trial is testing a new way to give ocrelizumab (Ocrevus) for multiple sclerosis — as a simple shot under the skin instead of a long IV infusion. About 75 adults with MS will receive increasing doses to see if the new form is safe and tolerable. If it works, it co…

This early-stage trial tests a new treatment called KYV-101 for people with progressive multiple sclerosis (MS) that hasn't improved with standard treatments. KYV-101 is a CAR T-cell therapy made from a patient's own immune cells, designed to attack the cells causing inflammation…

This study compares two versions of the drug ocrelizumab given as a shot under the skin in people with multiple sclerosis. The goal is to see if the new test version works the same as the current one. About 182 participants with relapsing or primary progressive MS will take part.

This early-stage trial tests a new treatment called CC-97540, which uses a patient's own immune cells engineered to target and destroy harmful immune cells. The study includes 120 people with relapsing or progressive multiple sclerosis or refractory myasthenia gravis. The main go…

This Phase 3 trial is testing whether a higher dose of the drug ocrelizumab (Ocrevus) can better slow disability progression in people with primary progressive multiple sclerosis (PPMS). About 769 adults with PPMS are receiving either the standard approved dose or a higher dose b…

This study is testing the drug ocrelizumab in 927 people with progressive multiple sclerosis (MS), a form of the disease that steadily worsens. Participants receive infusions every 24 weeks for about 4 years. The main goal is to see if the drug can stop or slow disability progres…

This phase 3 trial compares the experimental drug frexalimab to the approved drug teriflunomide in about 1,655 adults with relapsing multiple sclerosis. The main goal is to see if frexalimab reduces the number of relapses more effectively. Participants receive either frexalimab i…

This early-stage study tests an experimental cell therapy called P-CD19CD20-ALLO1 in 60 adults with multiple sclerosis. The main goal is to see if it is safe and how the body handles it. Researchers will also measure how long the cells last and how they affect the immune system.

This Phase 1 trial compares a new drug called RPH-035 to the approved MS drug Ocrevus. The study involves 180 adults with relapsing-remitting or secondary progressive multiple sclerosis who have flare-ups. Researchers are checking if RPH-035 behaves similarly in the body and has …

This study tests whether taking a 7-day course of oral antibiotics after hip or knee replacement surgery can prevent joint infections in patients at higher risk due to conditions like obesity, diabetes, or autoimmune disease. About 4,600 participants will receive one of three ant…

This study tests whether stimulating the vagus nerve through the ear, while doing a hand coordination task, can improve motor function in people with multiple sclerosis. Participants will receive either active or sham stimulation during 30-minute sessions over a month, with follo…

This study tests the drug ocrelizumab in 60 Chinese adults with two forms of multiple sclerosis (MS): relapsing MS and primary progressive MS. The goal is to see if it reduces relapses and controls disease activity. Participants receive ocrelizumab infusions, and researchers trac…

This early-phase study tests a new type of CAR-T cell therapy in 9 people with autoimmune diseases that have not responded well to standard treatments. The therapy uses specially engineered immune cells to target and attack faulty immune cells. The main goal is to check safety an…

This phase 2a trial tests a nasal spray called foralumab in 54 people with non-active secondary progressive multiple sclerosis (SPMS). The spray contains an antibody that aims to calm overactive immune cells in the brain. Participants will receive either a low dose, a high dose, …

This study aimed to test a new treatment called CABA-201, a CAR T-cell therapy made from a patient's own immune cells, for people with multiple sclerosis (MS). The goal was to see if it was safe and could control the disease by targeting and resetting the immune system. However, …

This phase 3 trial compares two drugs for primary progressive multiple sclerosis (PPMS), a form of MS that steadily worsens. About 985 adults with PPMS will receive either daily oral fenebrutinib or intravenous ocrelizumab (plus matching placebos) to see which better delays disab…

This early-stage trial tests clonal fetal mesenchymal stem cells (cfMSCs) in 100 people with severe immune-related disorders or tissue damage. The goal is to see if the cells are safe and can reduce symptoms. Participants have no other treatment options left.

This study tests an experimental drug called frexalimab in people with a type of progressive multiple sclerosis (MS) that is no longer causing relapses. The goal is to see if the drug can delay worsening disability compared to a placebo. About 943 adults aged 18 to 60 are taking …

This phase 3 trial tests whether the oral drug masitinib can slow disability worsening in people with progressive multiple sclerosis who do not have relapses. About 800 participants will receive either masitinib or a placebo for 96 weeks. The main goal is to see if masitinib dela…

This study looks at whether people over 50 with a stable, inactive form of secondary progressive multiple sclerosis can stop taking their disease-modifying drugs without getting worse. Researchers will track 250 participants for 2 years to see if stopping treatment leads to more …

This study tests whether N-acetyl cysteine (NAC), a supplement, can protect the brain in people with progressive multiple sclerosis (MS). About 98 adults with primary or secondary progressive MS will receive either NAC or a placebo for 15 months. Researchers will measure brain sh…

This early-phase trial tests whether a patient's own bone marrow stem cells, injected into the spinal fluid, can repair nerve damage caused by progressive multiple sclerosis. The study involves 18 adults with secondary or primary progressive MS. Researchers will measure changes i…

This phase 3 study tests an oral medication called IMU-838 against a placebo in about 1,100 adults with relapsing multiple sclerosis (MS). The goal is to see if the drug can reduce the number of relapses and new brain lesions over 72 weeks. Participants must be 18-55 years old wi…

This Phase 3 trial tests whether IMU-838 (vidofludimus calcium) can reduce relapses and brain lesions in adults with relapsing multiple sclerosis. Over 1,100 participants are randomly assigned to receive either the drug or a placebo for up to 72 weeks. The study is active but no …

This phase 3 trial tests whether ocrelizumab (Ocrevus) can slow disability progression in adults with primary progressive multiple sclerosis (PPMS). Over 1,000 participants receive either the drug or a placebo. The main goal is to see if the drug delays worsening of hand function…

This study aimed to test whether stem cells from amniotic fluid, injected into the spinal fluid, could safely help people with progressive multiple sclerosis (MS). The trial was designed for adults aged 18–60 with primary or secondary progressive MS. However, the study was withdr…

This program offers early access to an experimental drug called CNM-Au8 for up to 25 adults with multiple sclerosis (MS). It is designed for people who have no other treatment options. The goal is to provide the drug while researchers continue to study its safety and effectivenes…

This study looks at whether switching from natalizumab to cladribine tablets is safe and effective for people with relapsing forms of multiple sclerosis. About 40 adults aged 18-60 will take cladribine after stopping natalizumab. Researchers will track immune cell changes, relaps…

This program provides access to siponimod, a medication that helps control active secondary progressive multiple sclerosis (SPMS). It is for adult patients who have no satisfactory treatment options. Doctors can request the drug for eligible patients through a compassionate use p…

This study looks at people with relapsing-remitting multiple sclerosis who switched from the drug MabThera to a similar, lower-cost medicine called Rixathon. Researchers want to see if the switch changes signs of nerve damage, new brain lesions, relapses, or disability. They will…

This UK trial tests whether cladribine tablets, taken for just 8-10 days a year over two years, can slow the loss of hand function in people with advanced multiple sclerosis (MS). The study includes 204 participants with significant disability (EDSS 6.5-8.5). Half receive cladrib…

This trial tests whether custom-designed sensorimotor insoles, worn daily for six months, can improve balance and walking in people with multiple sclerosis. Fifty adults with MS (mild to moderate disability) will be randomly assigned to receive the insoles or continue their usual…

This study looks at whether improving diet quality and reducing calories can help physical function, thinking, pain, fatigue, mood, and anxiety in 100 adults with relapsing-remitting or secondary progressive multiple sclerosis. Participants receive prepared meals and behavioral s…

This early-stage study tests whether a novel light therapy, designed to reset the body's internal clock, is safe and can reduce fatigue in people with progressive multiple sclerosis. Twenty participants will receive the light therapy while researchers monitor side effects and mea…

This study aims to create a tool that predicts which patients with inflammatory rheumatic diseases (like rheumatoid arthritis, vasculitis, or polymyalgia rheumatica) will develop serious side effects from long-term steroid use. Researchers will collect routine medical data—such a…

This registry enrolls up to 1,000 women aged 12–55 with rheumatic or autoimmune diseases who are pregnant or planning pregnancy. Researchers will collect data from medical records and patient surveys to study pregnancy outcomes, disease activity, and medication use. No experiment…

This study looks at whether combining a special breathing technique (called acute intermittent hypoxia, or AIH) with mild electrical stimulation of leg muscles can boost brain-to-muscle signals in people with relapsing forms of multiple sclerosis. About 40 participants will have …

This study looks at immune cells from people with autoimmune diseases (like lupus), people with infections, and healthy volunteers. Researchers want to understand how these cells differ and what makes them attack the body in autoimmune conditions. The study involves blood and bon…